European interventional oncology device procedure volumes and revenues will grow moderately, driven by an expanding patient population, rising patient and physician awareness, improved reimbursement leading to adoption of premium-priced devices, launch of new products, and increased physician training on interventional oncology procedures. However, increasing competition in all market segments, coupled with ongoing cost constraints in the region and the impact of the COVID-19 pandemic, will limit the pace of revenue expansion.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Europe across a 10-year period.
COVID-19 will have a negative impact on the interventional oncology device market.
How will COVID-19 affect the different segments of the interventional oncology device market?
When will the market start to recover and at what pace will it do so?
Reimbursement will be an important factor in the adoption of interventional oncology procedures.
How do reimbursement policies vary among the different European countries covered?
How will different reimbursement policies impact the uptake of interventional oncology devices?
Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications, while novel indications such as prostate and pancreatic cancer represent new opportunities for growth.
What are the advantages and disadvantages of each type of ablation device offered by competitors and how do these differences affect adoption for different indications?
What are the major demographic, economic, and local trend differences across Europe that impact the adoption of these devices?
Radioembolization spheres continue to represent the largest segment of the embolization particle market, although the microsphere and DEB markets will also experience growth over the forecast period.
How will outcomes of trials like SIRFLOX and FOXFIRE affect the adoption and usage of radioembolization spheres?
What factors are contributing to the growth of the European microsphere and DEB markets?
How will the uptake of other embolization particles impact the PVA particle market?
How will the adoption of bioresorbable microspheres and DEBs impact the adoption of existing products?
- Interventional Oncology Devices - Market Insights - Europe
Author(s): Bishwjit Ghoshal, MBA
Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.
Follow Bishwjit on twitter: @Bishwjit_DRG